Matthias Mayerhofer

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin

Matthias Mayerhofer, Peter Valent, Wolfgang R. Sperr et al. · Blood · 2002 · 275 citations

Life Sciences, Cancer Biology, Molecular Biology +16

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides

Karl J. Aichberger, Matthias Mayerhofer, Maria‐Theresa Krauth et al. · Blood · 2004 · 252 citations · Full text

Medicine, Molecular Biology, Oncology +12

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

Karoline V. Gleixner, Matthias Mayerhofer, Karl J. Aichberger et al. · Blood · 2005 · 247 citations · Full text

Medicine, Cancer Biology, Pharmacology +12

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Harald Herrmann, Irina Sadovnik, Sabine Cerny‐Reiterer et al. · Blood · 2014 · 216 citations · Full text

Medicine, Hematology, Oncology +13

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia

Wolfgang Warsch, Karoline Kollmann, Eva Eckelhart et al. · Blood · 2011 · 188 citations · Full text

Medicine, Cancer Biology, Molecular Biology +8